Last updated: 2026-09-16 14:41:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Vistagen Therapeutics, Inc. (VTGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0,23, with a market capitalisation of $10,79M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,20 to $5,14. This page covers its latest market performance, valuation, price trends and company information.
$10,79M | |
$0,24 | |
$140,70 | |
$0,20 | |
$0,24 | |
152,70K | |
3,99M | |
-- | |
$5,14 | |
$0,20 | |
-- | |
-- |
Vistagen Therapeutics, Inc. (VTGN) is currently trading at $0,23 as of 2026-09-16 14:39:00, down 1,31% ($0,00) from the previous close of $0,24
During today's regular trading session, VTGN has traded between $0,20 and $140,70, with a trading volume of 152,70K shares. The current price is near the lower end of today's range.
Over the past seven days, Vistagen Therapeutics, Inc. (VTGN) moved from $0,24 to $0,23, representing a decline of 4,04% ($0,01).
The stock traded between $0,23 and $0,26 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 365,05 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,7%
VTGN is currently trading at $0,23, placing it 0,7% of the way from its 52-week low of $0,20 to its 52-week high of $5,14. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 41 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vistagen Therapeutics, Inc. (VTGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.